Keyword: Arcus Biosciences
William Grossman joins the immuno-oncology biotech as it gears up for readouts from early-phase trials of its most advanced candidates.
Seeking further returns from Taiho Ventures, Taiho Pharma just decided to multiply its investment pool sixfold to $300 million.
Arcus Biosciences and Infinity Pharmaceuticals plan to mix their lead programs in triple-combination immunotherapy trials in breast and ovarian cancer.
Months after raising a $107 million series C, Arcus Biosciences has filed for a $100 million IPO.
Immuno-oncology startup Arcus Bioscience has got off another impressive round of funding, just over a year after emerging from stealth with $120 million.
Arcus has signed a deal with Taiho that provides a healthy cash injection while keeping rights in the U.S. and other markets in hand.
Arcus inked an $816 million deal for a PD-1 drug developed by Chinese firms WuXi Biologics and Gloria Pharmaceuticals.
Deborah Dunsire has achieved the rare feat, on International Women’s Day no less, of becoming CEO of an early-stage biotech after being officially named as XTuit Pharmaceuticals’ leader today.
A biopharma and startup vet aim to build an immuno-oncology powerhouse to offer a rational approach to combination therapy.
Fresh off the $1.25 billion Flexus sale, Terry Rosen is aiming to build a major immuno-oncology biopharma from the ground up with upstart Arcus Biosciences.